

Grisel J Lopez

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1333889/grisel-j-lopez-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33
papers

1,416
citations

13
h-index

34
g-index

34
ext. papers

1,807
ext. citations

6.5
avg, IF

4.52
L-index

#	Paper	IF	Citations
33	No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance.. <i>Movement Disorders</i> , 2022 ,	7	2
32	Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5842	6.3	0
31	Gaucher Disease and Heart Failure of Unknown Origin. <i>American Journal of Medicine</i> , 2021 , 134, 745-748	2.4	
30	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021 , 53, 294-303	36.3	31
29	Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. <i>Molecular Genetics and Metabolism</i> , 2020 , 130, 164-169	3.7	14
28	Longitudinal Positron Emission Tomography of Dopamine Synthesis in Subjects with GBA1 Mutations. <i>Annals of Neurology</i> , 2020 , 87, 652-657	9.4	3
27	Substrate reduction therapy for GBA1-associated Parkinsonism: Are we betting on the wrong mouse?. <i>Movement Disorders</i> , 2020 , 35, 228-230	7	6
26	Clinical evaluation of sibling pairs with gaucher disease discordant for parkinsonism. <i>Movement Disorders</i> , 2020 , 35, 359-365	7	6
25	Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism. <i>Trends in Molecular Medicine</i> , 2020 , 26, 913-923	11.5	6
24	The natural history of type 2 Gaucher disease in the 21st century: A retrospective study. <i>Neurology</i> , 2020 , 95, e2119-e2130	6.5	8
23	EEG abnormalities in patients with chronic neuronopathic Gaucher disease: A retrospective review. <i>Molecular Genetics and Metabolism</i> , 2020 , 131, 358-363	3.7	4
22	Five-parameter evaluation of dysphagia: A novel prognostic scale for assessing neurological decline in Gaucher disease type 2. <i>Molecular Genetics and Metabolism</i> , 2019 , 127, 191-199	3.7	5
21	Variation in cognitive function over time in Gaucher disease type 3. <i>Neurology</i> , 2019 , 93, e2272-e2283	6.5	10
20	Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 50, 108-112	3.6	28
19	Cardiac sympathetic denervation predicts PD in at-risk individuals. <i>Parkinsonism and Related Disorders</i> , 2018 , 52, 90-93	3.6	20
18	Glucocerebrosidase mutations and parkinsonism: how much does the mutation matter?. <i>Journal of Xiangya Medicine</i> , 2018 , 3, 1-1	0.1	3
17	Alleles with more than one mutation can complicate genotype/phenotype studies in Mendelian disorders: Lessons from Gaucher disease. <i>Molecular Genetics and Metabolism</i> , 2018 , 125, 1-3	3.7	8

16	Efferocytosis is impaired in Gaucher macrophages. <i>Haematologica</i> , 2017 , 102, 656-665	6.6	8
15	Type 2 Gaucher disease in an infant despite a normal maternal glucocerebrosidase gene. <i>American Journal of Medical Genetics, Part A</i> , 2017 , 173, 3211-3215	2.5	4
14	Gaucher disease: Progress and ongoing challenges. <i>Molecular Genetics and Metabolism</i> , 2017 , 120, 8-21	3.7	72
13	A New Glucocerebrosidase Chaperone Reduces α -Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. <i>Journal of Neuroscience</i> , 2016 , 36, 7441-52	6.6	150
12	Clinical course and prognosis in patients with Gaucher disease and parkinsonism. <i>Neurology: Genetics</i> , 2016 , 2, e57	3.8	23
11	Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 549-562	1.1	1
10	The clinical management of Type 2 Gaucher disease. <i>Molecular Genetics and Metabolism</i> , 2015 , 114, 110-122	3.7	71
9	Bilateral Femoral Osteolytic Lesions in a Patient with Type 3 Gaucher Disease. <i>Molecular Genetics and Metabolism Reports</i> , 2015 , 5, 107-109	1.8	3
8	Studies of glucocerebrosidase provide new therapeutic targets for parkinsonism. <i>Future Neurology</i> , 2014 , 9, 407-409	1.5	
7	Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. <i>Science Translational Medicine</i> , 2014 , 6, 240ra73	17.5	72
6	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. <i>JAMA Neurology</i> , 2013 , 70, 727-35	17.2	285
5	The link between the GBA gene and parkinsonism. <i>Lancet Neurology</i> , 2012 , 11, 986-98	24.1	353
4	The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. <i>Brain</i> , 2012 , 135, 2440-8	11.2	67
3	Autosomal recessive mutations in the development of Parkinson's disease. <i>Biomarkers in Medicine</i> , 2010 , 4, 713-21	2.3	11
2	The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. <i>Archives of Neurology</i> , 2008 , 65, 1353-7		142
1	Imaging and genetics in Parkinson's disease: assessment of the GBA1 mutation. <i>Journal of Neurology</i> ,	5.5	